Corcept Therapeutics CORT Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's operating lease right-of-use assets in other assets?
- Corcept Therapeutics (CORT) reported operating lease right-of-use assets in other assets of $7.2M in Q1 2026.
- How has Corcept Therapeutics's operating lease right-of-use assets in other assets changed year-over-year?
- Corcept Therapeutics's operating lease right-of-use assets in other assets increased by 39.8% year-over-year, from $5.15M to $7.2M.
- What is the long-term trend for Corcept Therapeutics's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Corcept Therapeutics's operating lease right-of-use assets in other assets has grown at a 12.8% compound annual growth rate (CAGR), from $2.51M to $4.58M.